Healthcare Service Provider
26 companies listed on NSE in this sector
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Consolidated revenue grew 30.14% YoY to INR 96.47 Cr. Molecular Diagnostics (Standalone Non-COVID) revenue grew 37.66% YoY to INR 78.13 Cr, while Agrochemicals revenue declined 10....
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Standalone revenue grew by 29.32% to INR 129.16 Cr in FY25, while H1 FY26 consolidated revenue reached INR 137.49 Cr, a 23.38% YoY increase. The diagnostic segment is a primary dri...
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Vinchurkar Diagnostics (Target Entity) revenue grew 8.18% in FY24 (INR 444.53 Lakhs) and 0.2% in FY25 (INR 445.44 Lakhs). Porteus Medical LLP and Primacare Diagnostic LLP contribut...
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
No documents found
Not disclosed in available documents.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
While absolute revenue figures are not disclosed, the Net Capital Turnover Ratio improved by 43.12% (from 5.96 to 8.53), indicating significantly higher revenue generation efficien...
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Not disclosed in available documents. The company has not provided specific percentage growth for its imaging or pathology segments.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
Investment analysis available. Click to view detailed financial performance, growth strategy, and risk assessment.
